Literature DB >> 29958537

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Linda M Liau1, Keyoumars Ashkan2, David D Tran3, Jian L Campian4, John E Trusheim5, Charles S Cobbs6, Jason A Heth7, Michael Salacz8, Sarah Taylor8, Stacy D D'Andre9, Fabio M Iwamoto10, Edward J Dropcho11, Yaron A Moshel12, Kevin A Walter13, Clement P Pillainayagam14, Robert Aiken15, Rekha Chaudhary16, Samuel A Goldlust17, Daniela A Bota18, Paul Duic19, Jai Grewal20, Heinrich Elinzano21, Steven A Toms21, Kevin O Lillehei22, Tom Mikkelsen23, Tobias Walbert23, Steven R Abram24, Andrew J Brenner25, Steven Brem26, Matthew G Ewend27, Simon Khagi27, Jana Portnow28, Lyndon J Kim29, William G Loudon30, Reid C Thompson31, David E Avigan32, Karen L Fink33, Francois J Geoffroy34, Scott Lindhorst35, Jose Lutzky36, Andrew E Sloan37, Gabriele Schackert38, Dietmar Krex38, Hans-Jorg Meisel39, Julian Wu40, Raphael P Davis41, Christopher Duma42, Arnold B Etame43, David Mathieu44, Santosh Kesari45, David Piccioni45, Manfred Westphal46, David S Baskin47, Pamela Z New47, Michel Lacroix48, Sven-Axel May49, Timothy J Pluard50, Victor Tse51, Richard M Green52, John L Villano53, Michael Pearlman54, Kevin Petrecca55, Michael Schulder56, Lynne P Taylor57, Anthony E Maida58, Robert M Prins59, Timothy F Cloughesy59, Paul Mulholland60, Marnix L Bosch61.   

Abstract

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.

Entities:  

Year:  2018        PMID: 29958537      PMCID: PMC6026340          DOI: 10.1186/s12967-018-1552-1

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


Correction to: J Transl Med (2018) 16:142 10.1186/s12967-018-1507-6

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section. Incorrect author name upon publication: Tobias Walpert The correct author name: Tobias Walbert The affected sentence in the Methods section upon publication, with the error marked in bold: In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at < 150 °C [22]. The corrected sentence, with the corrected temperature marked in bold: In general, approximately 2 g of tumor tissue was needed to produce the full ten doses for the 36-month treatment and follow-up schedule. The vaccine was aliquoted in individual doses and cryopreserved at < − 150 °C [22]. The reference which is cited in the above sentence can be reviewed in the original article.
  1 in total

1.  First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Authors:  Linda M Liau; Keyoumars Ashkan; David D Tran; Jian L Campian; John E Trusheim; Charles S Cobbs; Jason A Heth; Michael Salacz; Sarah Taylor; Stacy D D'Andre; Fabio M Iwamoto; Edward J Dropcho; Yaron A Moshel; Kevin A Walter; Clement P Pillainayagam; Robert Aiken; Rekha Chaudhary; Samuel A Goldlust; Daniela A Bota; Paul Duic; Jai Grewal; Heinrich Elinzano; Steven A Toms; Kevin O Lillehei; Tom Mikkelsen; Tobias Walbert; Steven R Abram; Andrew J Brenner; Steven Brem; Matthew G Ewend; Simon Khagi; Jana Portnow; Lyndon J Kim; William G Loudon; Reid C Thompson; David E Avigan; Karen L Fink; Francois J Geoffroy; Scott Lindhorst; Jose Lutzky; Andrew E Sloan; Gabriele Schackert; Dietmar Krex; Hans-Jorg Meisel; Julian Wu; Raphael P Davis; Christopher Duma; Arnold B Etame; David Mathieu; Santosh Kesari; David Piccioni; Manfred Westphal; David S Baskin; Pamela Z New; Michel Lacroix; Sven-Axel May; Timothy J Pluard; Victor Tse; Richard M Green; John L Villano; Michael Pearlman; Kevin Petrecca; Michael Schulder; Lynne P Taylor; Anthony E Maida; Robert M Prins; Timothy F Cloughesy; Paul Mulholland; Marnix L Bosch
Journal:  J Transl Med       Date:  2018-05-29       Impact factor: 5.531

  1 in total
  6 in total

Review 1.  The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.

Authors:  Jia-Shu Chen; Ross Clarke; Alexander F Haddad; Elaina J Wang; Michel Lacroix; Indra Neil Sarkar; Ramin Zand; Elizabeth S Chen; Steven A Toms
Journal:  J Neurooncol       Date:  2022-01-04       Impact factor: 4.130

Review 2.  Newly Diagnosed Glioblastoma: A Review on Clinical Management.

Authors:  Rimas V Lukas; Derek A Wainwright; Erik Ladomersky; Sean Sachdev; Adam M Sonabend; Roger Stupp
Journal:  Oncology (Williston Park)       Date:  2019-03-13       Impact factor: 2.990

Review 3.  Immunotherapy Against Gliomas: is the Breakthrough Near?

Authors:  Rimas V Lukas; Derek A Wainwright; Craig M Horbinski; Fabio M Iwamoto; Adam M Sonabend
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 4.  Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.

Authors:  Benedikt Jacobs; Veronika Gebel; Lukas Heger; Victoria Grèze; Hansjörg Schild; Diana Dudziak; Evelyn Ullrich
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 5.  Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.

Authors:  Shaoping Shen; Ling Chen; Jialin Liu; Lin Yang; Mengna Zhang; Lingxiong Wang; Rong Zhang; Yasushi Uemura; Qiyan Wu; Xinguang Yu; Tianyi Liu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

6.  Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes.

Authors:  Matteo Simonelli; Pasquale Persico; Arianna Capucetti; Claudia Carenza; Sara Franzese; Elena Lorenzi; Angelo Dipasquale; Agnese Losurdo; Laura Giordano; Federico Pessina; Pierina Navarria; Letterio S Politi; Domenico Mavilio; Massimo Locati; Silvia Della Bella; Armando Santoro; Raffaella Bonecchi
Journal:  Neurooncol Adv       Date:  2021-11-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.